NYB
AI-first drug discovery and nutraceuticals company that advances therapeutics and nutraceuticals through an integrated discovery platform.
Where NYB ranks
Current edition · updated Oct 20, 2026About NYB
AI-first drug discovery and nutraceuticals company that advances therapeutics and nutraceuticals through an integrated discovery platform.
Products
Agentic AI compound discovery platform that unifies proprietary AI models, curated natural datasets, and scientific workflows into a single connected environment.
Proprietary AI model for bioactivity prediction using graph neural networks, outperforming nine leading methods by an average of 27.03% in bioactivity prediction correlation.
Proprietary digital natural compound library of 1.5M+ compounds from over 50,000 underexplored species, integrating biology, chemistry, and traditional usage for discovery insig...
End-to-end nutraceutical research and formulation platform providing mechanism-guided formulation, AI-assisted tools, preclinical evaluation, formulation development, and OEM/cu...
What customers say
“We aim to be the platform of choice for people looking to discover compounds for drugs and other uses. Scanning natural compound data requires powerful GPUs that consume a lot of energy. That’s why we want to collaborate with organizations like HPE, NVIDIA, and Equinix, who have extensive experience in developing and running data centers, scaling GPUs, and managing IT operations,”
Security and compliance
No security details published yet
NYB hasn't published certifications or security practices that we could find. Ask their team for audit reports.
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim NYB